BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kröner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc 2019;90:881-92. [PMID: 31526811 DOI: 10.1016/j.gie.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rovedatti L, Lenti MV, Vanoli A, Feltri M, De Grazia F, Di Sabatino A. Nivolumab-associated active neutrophilic gastritis. J Clin Pathol 2020;73:605-6. [PMID: 32161070 DOI: 10.1136/jclinpath-2020-206540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bazarbashi AN, Dolan RD, Yang J, Perencevich ML. Combination Checkpoint Inhibitor-Induced Hemorrhagic Gastritis. ACG Case Rep J 2020;7:e00402. [PMID: 33062778 DOI: 10.14309/crj.0000000000000402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol. 2020;27:e486-e494. [PMID: 33173388 DOI: 10.3747/co.27.6251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol 2020;16:201-10. [PMID: 32212243 DOI: 10.1111/ajco.13332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Mendo R, Figueiredo P, Mascarenhas L. Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation. GE Port J Gastroenterol 2021;28:150-2. [PMID: 33791404 DOI: 10.1159/000509196] [Reference Citation Analysis]